Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Main|Search|PHGKB
Search PHGKB:

Last Posted: Jun 09, 2023
spot light Highlights

Cost-Effectiveness Analysis in Public Health Genomics and Precision Health: Recent Findings, Methodologic Issues, and the Path Forward
CDC Public Health Genomics Webinar, October 26, 2023 Brand

Dr David Veenstra from the University of Washington in Seattle will review the field as a whole and his research projects including evaluation of the cost-effectiveness of population-level genomic screening, pharmacogenomics in diverse populations, decision modeling techniques to assess evidence thresholds, and stakeholder preferences for precision medicine. He will address recent findings, methodologic issues and the path forward.

Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021
CDC Visual Abstracts, June 2023 Brand

Severe COVID-19 outcomes, including hospitalization, IMV, ICU admission, and death, are more frequent in PI patients than in non-PI patients seen in emergency departments. These results provide real-world evidence that PI is a risk factor for adverse COVID-19 outcomes.

Rigorous and rapid evidence assessment in digital health with the evidence DEFINED framework
J Silberman et al, NPJ Digital Medicine, May 31, 2023

We propose a framework to assess Evidence in Digital health for EFfectiveness of INterventions with Evaluative Depth (Evidence DEFINED). Designed for real-world use, the Evidence DEFINED Quick Start Guide may help streamline DHI assessment. A checklist is provided summarizing high-priority evidence considerations in digital health. Evidence-to-recommendation guidelines are proposed, specifying degrees of adoption that may be appropriate for a range of evidence quality levels. Evidence DEFINED differs from prior frameworks in its inclusion of unique elements designed for rigor and speed.

When Is a High Lipoprotein (a) Concentration Too High?-The Need for Diverse Population-Based Samples.
Sadiya S Khan et al. JAMA Cardiol 2023 5

Preclinical, epidemiologic, and genomic studies identify lipoprotein (a) (Lp[a]) as a risk factor for atherosclerotic cardiovascular disease (ASCVD). Lp(a) is a low-density lipoprotein (LDL)–like particle that is bound to apolipoprotein(a) and is causally implicated in the pathogenesis of ASCVD. Despite growing evidence supporting the potential utility of Lp(a) in risk stratification for ASCVD, challenges remain in defining a cut point for what constitutes a high Lp(a) concentration. These include variation observed in Lp(a) concentrations across racial and ethnic groups, as well as differences in accuracy across various assays.

Search Result Summary


Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP